Sofosbuvir may be a potential anti-sars-cov-2 rdrp drug

Mohamed Nabil Ibrahim; Abdo Abdellah Elfiky

doi:10.3844/ajbbsp.2021.205.207

Sofosbuvir may be a potential anti-sars-cov-2 rdrp drug

Mohamed Nabil Ibrahim, Abdo Abdellah Elfiky

Research output: Contribution to journal › Article › peer-review

Abstract

The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.

Original language	English (US)
Pages (from-to)	205-207
Number of pages	3
Journal	American Journal of Biochemistry and Biotechnology
Volume	17
Issue number	2
DOIs	https://doi.org/10.3844/ajbbsp.2021.205.207
State	Published - May 10 2021
Externally published	Yes

Bibliographical note

KAUST Repository Item: Exported on 2022-06-21
Acknowledgements: Computational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University , is acknowledged.
This publication acknowledges KAUST support, but has no KAUST affiliated authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3844/ajbbsp.2021.205.207

Cite this

@article{856a5bd195fc4f888dc65193f651b307,

title = "Sofosbuvir may be a potential anti-sars-cov-2 rdrp drug",

abstract = "The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.",

author = "Ibrahim, {Mohamed Nabil} and Elfiky, {Abdo Abdellah}",

note = "KAUST Repository Item: Exported on 2022-06-21 Acknowledgements: Computational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University , is acknowledged. This publication acknowledges KAUST support, but has no KAUST affiliated authors.",

year = "2021",

month = may,

day = "10",

doi = "10.3844/ajbbsp.2021.205.207",

language = "English (US)",

volume = "17",

pages = "205--207",

journal = "American Journal of Biochemistry and Biotechnology",

issn = "1558-6332",

publisher = "Science Publications",

number = "2",

}

TY - JOUR

T1 - Sofosbuvir may be a potential anti-sars-cov-2 rdrp drug

AU - Ibrahim, Mohamed Nabil

AU - Elfiky, Abdo Abdellah

N1 - KAUST Repository Item: Exported on 2022-06-21 Acknowledgements: Computational support from the King Abdullah University of Science and Technology (KAUST HPC allocation grant “K1482”) and COVID-19 Grant by Cairo University , is acknowledged. This publication acknowledges KAUST support, but has no KAUST affiliated authors.

PY - 2021/5/10

Y1 - 2021/5/10

N2 - The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.

AB - The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.

UR - http://hdl.handle.net/10754/679205

UR - https://thescipub.com/abstract/10.3844/ajbbsp.2021.205.207

UR - http://www.scopus.com/inward/record.url?scp=85107233257&partnerID=8YFLogxK

U2 - 10.3844/ajbbsp.2021.205.207

DO - 10.3844/ajbbsp.2021.205.207

M3 - Article

SN - 1558-6332

VL - 17

SP - 205

EP - 207

JO - American Journal of Biochemistry and Biotechnology

JF - American Journal of Biochemistry and Biotechnology

IS - 2

ER -

Sofosbuvir may be a potential anti-sars-cov-2 rdrp drug

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this